

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUNPHARMA
复星医药

上海復星醫藥（集團）股份有限公司
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock code: 02196)

**POLL RESULTS OF THE RESOLUTIONS PROPOSED AT
THE 2016 THIRD EXTRAORDINARY GENERAL MEETING
HELD ON 29 SEPTEMBER 2016**

The board (the “**Board**”) of directors (the “**Directors**”) of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “**Company**”) is pleased to announce the poll results of the 2016 third extraordinary general meeting (the “**EGM**”) held at Shanghai Film Art Center, No. 160 Xinhua Road, Shanghai, the People's Republic of China on Thursday, 29 September 2016 at 2:00 p.m..

Reference is made to the notice of the EGM and the circular of the Company (the “**Circular**”), dated 11 August 2016. Unless the context otherwise requires, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

As at the date of the EGM, (i) the total number of the issued shares of the Company (the “**Shares**”) was 2,314,075,364 Shares, comprising 1,910,791,364 A Shares and 403,284,000 H Shares; and (ii) holders of 2,314,075,364 Shares (or authorized proxies) were entitled to attend and vote on the resolutions proposed at the EGM. There were no Shares entitling the Shareholders to attend and vote only against the resolutions at the EGM.

To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, no Shareholder was required to abstain from voting at the EGM.

The EGM were convened in compliance with the requirements of the People's Republic of China Company Law and the articles of association of the Company (the “**Articles of Association**”), and was chaired by Mr. Chen Qiyu, the chairman of the Company.

In compliance with the requirements of the Hong Kong Listing Rules and Article 115 of the Articles of Association, BDO Limited, Grandall Law Firm (Shanghai), the Company's PRC legal advisers, Shareholder's representative and members of the supervisory committee of the Company acted as the scrutineers for the vote-counting at the EGM.

ATTENDANCE AT THE EGM

Set out below are the details of the Shareholders and authorized proxies present at the EGM:

Number of Shareholders and authorized proxies	121
<i>Including:</i> Number of A Shareholders	120
Number of H Shareholders	1
Total number of Shares carrying voting rights (shares)	1,191,206,789
<i>Including:</i> Total number of Shares carrying voting rights held by A Shareholders	1,033,144,478
Total number of Shares carrying voting rights held by H Shareholders	158,062,311
Percentage of the total number of Shares of the Company carrying voting rights (%)	51.4766%
<i>Including:</i> Number of A Shares as a percentage of the number of Shares of the Company carrying voting rights	44.6461%
Number of H Shares as a percentage of the number of Shares of the Company carrying voting rights	6.8305%

POLL RESULTS OF THE RESOLUTIONS PROPOSED AT THE EGM

All resolutions at the EGM were voted by poll. The poll results in respect of the resolutions proposed at the EGM are as follows:

Special Resolution		Number of valid votes (%)		
		For	Against	Abstain
1.	To consider and approve the resolution in relation to the proposed acquisition of the controlling interest in Gland Pharma Limited.	1,176,697,763 (98.7820%)	1,013,357 (0.0851%)	13,495,669 (1.1329%)
As more than two thirds of the votes were cast in favour of this resolution, the resolution was duly passed as a special resolution.				
Ordinary Resolution		Number of valid votes (%)		
		For	Against	Abstain
2.	To consider and approve the resolution in relation to the proposal on the provision of additional guarantee limit in respect of Fosun Industrial Co., Limited.	1,126,200,974 (94.5429%)	52,005,815 (4.3658%)	13,000,000 (1.0913%)
As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.				

As certified by and stated in the legal opinion issued by Grandall Law Firm (Shanghai), the Company's PRC legal advisers, the convening and holding of the EGM are in compliance with requirements of the relevant laws, administrative regulations, the Rules of General Meetings of Listed Companies issued by China Securities Regulatory Commission and the Articles of Association, the qualifications of the attendees of the EGM and the convener are legally valid, and the voting procedures and voting results of the EGM are legally valid.

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Qiyu
Chairman

Shanghai, the People's Republic of China
29 September 2016

As at the date of this announcement, the executive Directors are Mr. Chen Qiyu, Mr. Yao Fang and Mr. Wuyifang; the non-executive Directors are Mr. Guo Guangchang, Mr. Wang Qunbin, Ms. Kang Lan and Mr. Wang Can; and the independent non-executive Directors are Mr. Cao Huimin, Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin and Mr. Wai Shiu Kwan Danny.

** for identification purposes only*